Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04849858 · ClinicalTrials.gov registry record · Phase 3
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
A Phase 3 study, sponsored by University of California, Irvine.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT04849858: Clinical Trial Phase 3 study, sponsored by University of California, Irvine.
NCT04849858 is a Phase 3 study that was terminated before completion, run by University of California, Irvine. The registered enrollment target is 13 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04849858, a Phase 3 study, was terminated before completion, sponsored by University of California, Irvine.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and lowers your risk of post-operative common side effects of surgery and narcotic pain medications.
Primary Outcome
Morphine equivalents (milligrams)
Interventions
- DRUG Bupivacaine
- DRUG Liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2023-01-13 |
| Phase | Phase 3 |
Why NCT04849858 stopped before completion
NCT04849858 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT04849858 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04849858 about?
NCT04849858 is a clinical study titled "Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures". The purpose of this research study is to find out which type of transversus abdomens plane (TAP) and block (bupivacaine, liposomal bupivacaine or liposomal bupivacaine with re-dosing at 48-60 hours) improves your pain control and lowers your risk of post-operative common side effects of surgery and ...
What is the current status of trial NCT04849858?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2019-05-20. Estimated completion is 2023-01-13.
What interventions are being tested in trial NCT04849858?
The interventions under investigation include: Bupivacaine (DRUG), Liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT04849858?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04849858's enrollment target sits among peer trials
13 1984th of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI